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Abstract. Cervical cancer is the second most common cancer 
amongst South African women and is the leading cause of 
cancer-associated mortality in this region. Several international 
studies on radiation-induced DNA damage in lymphocytes of 
cervical cancer patients have remained inconclusive. Despite 
the high incidence of cervical cancer in South Africa, and 
the extensive use of radiotherapy to treat it, the chromosomal 
radiosensitivity of South African cervical cancer patients 
has not been studied to date. Since a high number of these 
patients are human immunodeficiency virus (HIV)‑positive, 
the effect of HIV infection on chromosomal radiosensitivity 
was also investigated. Blood samples from 35 cervical cancer 
patients (20 HIV‑negative and 15 HIV‑positive) and 20 healthy 
controls were exposed to X-rays at doses of 6 MV of 2 and 
4 Gy in vitro. Chromosomal radiosensitivity was assessed 
using the micronucleus (MN) assay. MN scores were obtained 
using the Metafer 4 platform, an automated microscopic 
system. Three scoring methods of the MNScore module of 
Metafer were applied and compared. Cervical cancer patients 
had higher MN values than healthy controls, with HIV‑positive 
patients having the highest MN values. Differences between 
groups were significant when using a scoring method that 
corrects for false positive and false negative MN. The present 
study suggested increased chromosomal radiosensitivity in 
HIV‑positive South African cervical cancer patients.
Introduction
Cervical cancer is the most common cancer type amongst 
women in Sub-Saharan Africa, with an age-standardized 
incidence rate of 34.8 per 105 females (1). Cervical cancer 
is also the leading cause of cancer-associated mortality 
amongst women in this region, with 22.5 per 105 women 
dying from the disease annually (1). It is well‑established that 
infection with oncogenic Human Papilloma Viruses (HPV) 
is the main cause of cervical cancer (2,3). The high incidence 
of cervical cancer in Africa is likely due to a combination of 
factors. These include lack of awareness of the disease and its 
causes, as well as challenges in implementing regular HPV 
Papanicolaou (Pap)‑smear screenings and HPV vaccinations, 
which have only recently been introduced into the South 
African health care system (4‑6). While a large number of 
women are infected with the HPV virus, not all of them 
develop cervical cancer (7). Heritability studies have shown 
that susceptibility to cervical cancer may be genetic (8) and 
recent studies have reported an association between cervical 
cancer and genes involved in DNA damage repair, including 
APE1, XRCC2, XRCC3, ERCC1, ERCC2, ERCC4 and 
ATM (9‑12).
Enhanced chromosomal radiosensitivity is associated 
with defects in genes involved in DNA damage repair (13). A 
possible inherited basis for radiosensitivity was first indicated 
by studies on patients with rare genetic syndromes, including 
Ataxia Telangiectasia and Nijmegen breakage syndrome (13). 
These patients were shown to display chromosomal radiosen-
sitivity not only by clinical observations, but also by in vitro 
assays (14). Patients with these syndromes have germline 
mutations in genes involved in DNA damage repair and 
also display predisposition to numerous cancer types. Their 
increased chromosomal radiosensitivity encouraged inves-
tigations demonstrating an enhanced in vitro chromosomal 
radiosensitivity in patients with various cancer types, including 
breast, head and neck and prostate cancer (15‑18). Mutations 
in DNA repair genes not only lead to increased chromosomal 
radiosensitivity in these patients but may also predispose them 
to the development of cancer (13,17,19,20). The chromosomal 
radiosensitivity of lymphocytes of cervical cancer patients has 
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been investigated in vitro using a variety of cytogenetic assays, 
however, results have been inconclusive (21‑24).
A well-established method to measure chromosomal 
radiosensitivity is the micronucleus (MN) assay, which quan-
tifies residual chromosomal damage resulting from mis‑or 
non-repaired double-strand breaks after exposure to radia-
tion. This assay can be performed on lymphocytes, which are 
an attractive model for radiosensitivity studies, as they are 
easily obtainable through venepuncture. MN scoring in this 
assay can be automated with an MN scoring module of the 
Metafer 4 platform. The MNScore micronucleus software 
module allows automated screening of binucleate cells and the 
subsequent scoring of MN in these cells (25). In this system, 
various scoring methods can be utilized that involve varying 
degrees of visual validation of automated scoring to correct 
for false positive and false negative MN and reject unsuitable 
cells (26,27). The benefits and challenges of using the MN 
assay with the Metafer 4 platform have been documented 
elsewhere (26‑32).
A study performed by our group (33) has previously shown 
that individuals infected with human immunodeficiency 
virus (HIV) are more chromosomally radiosensitive than 
HIV‑negative individuals. In South Africa, ~5.7 million people 
are HIV‑positive (34). HIV, HPV and cervical cancer are 
epidemiologically associated and in 1993, invasive cervical 
carcinoma was classified as an acquired immune deficiency 
syndrome‑defining illness by the United States Centers for 
Disease Control and Prevention (35). Rates of HPV infection 
increase with decreasing CD4‑cell count (36) and studies have 
shown that HPV infection still persists in a high proportion 
of patients receiving highly active anti‑retroviral therapy (37). 
Due to the high rate of HIV in Africa and its association with 
cervical cancer, it is likely that a significant proportion of 
cervical cancer patients seeking treatment are HIV‑positive.
The aim of the present study was to investigate the in vitro 
chromosomal radiosensitivity in South African cervical cancer 
patients by means of the MN assay using a case-control study 
design. Concurrently, various scoring methods were evaluated 
when using the MN assay with the Metafer 4 platform. Due 
to the high rate of HIV in South Africa and its association 
with cervical cancer, the effect of the HIV infection status on 
chromosomal radiosensitivity of patients was also assessed.
Patients and methods
Study population. Blood samples were obtained via vene-
puncture from a total of 35 cervical cancer patients (mean age, 
46 years) and 20 healthy female controls (mean age, 41 years). 
Among the patients with cervical cancer, 15 were infected 
with HIV (mean age, 43 years) and 20 were HIV‑negative 
(mean age, 49 years). Patients were recruited from the public 
Charlotte Maxeke Johannesburg Academic Hospital (CMJAH; 
Johannesburg, South Africa), where they underwent a curative 
hysterectomy or radiotherapy. Clinical information on the 
patients was obtained from questionnaires and hospital files. 
None of the patients had received any chemotherapy or radio-
therapy prior to sample collection. The tumors of all patients 
were squamous cell carcinoma. The majority of the patients had 
late‑stage disease, five had early‑stage disease and the disease 
stage was unknown for one patient. The healthy controls were 
staff members at CMJAH. All blood donors provided written 
informed consent and the study was approved by the Human 
Research Ethics Committee of University of Witwatersrand 
(Johannesburg, South Africa; no. M110230).
Irradiation and micronucleus assay. Lymphocyte cultures 
were established by adding 0.5 ml heparinized blood to 4.5 ml 
RPMI‑1640 medium (BioWhittaker, Walkersville, MD, USA) 
supplemented with 13% foetal bovine serum (Gibco‑BRL, 
Invitrogen Life Technologies, Inc., New York, NY, USA) and 
antibiotics (50 U/ml penicillin and 50 mg/ml streptomycin; 
Gibco‑BRL) in tissue culture flasks (25 cm2). The medium was 
pre‑warmed to 37˚C and gassed (5% CO2/95% air). The cells 
were exposed to irradiation at the Radiation Oncology Unit of 
CMJAH. Culture flasks were placed in a Phantom‑water tank 
(PolyScience, Warrington, PA, USA) at room temperature 
and irradiated with X‑rays using a 6 MV photon beam from 
a medical linear accelerator (Siemens Healthcare, Erlangen, 
Germany). Culture flasks were placed 100 cm away from the 
radiation source with an angle of 90 degrees. The field size at 
the depth of the sample was 10x10 cm. Samples were irradiated 
with 2 Gray (Gy) and 4 Gy at a dose rate of ~1.33 Gy/min. A 
0 Gy dose was used for the sham-irradiated control. For each 
irradiation dose, two co-cultures were set up. Immediately 
after irradiation, the lymphocytes were stimulated with 100 µl 
phytohaemagglutinin (1‑mg/ml stock solution; Sigma‑Aldrich, 
St Louis, MO, USA) and 23 h later, 20 µl cytochalasin B (stock 
solution of 1.5 mg/ml; Sigma‑Aldrich) was added to block 
cytokinesis. Cells were harvested at 70 h after stimulation 
using a cold (4˚C) hypotonic shock with 7 ml 0.075 M KCl 
(Merck, Darmstadt, Germany). This was followed by fixation 
in methanol/acetic acid/Ringer's solution (0.9% NaCl) (4:1:5) 
(Merck) at 4˚C overnight. Subsequently, cells were fixed 
another three times with methanol/acetic acid (4:1) (Merck). 
Cell suspensions were dropped onto coded slides and stored 
at 4˚C overnight. Slides were mounted with vectashield 
containing DAPI (Vector Laboratories, Brussels, Belgium) 
prior to automatized scanning using the Metafer 4 platform 
(MetaSystems, Altlussheim, Germany) (28,32).
Scoring. Microscopic analysis was performed with the 
Metafer 4 platform connected to a motorized Zeiss 
AxioImager M1 microscope (Zeiss, Gottingen, Germany). 
The MetaSystems MNScore software module identifies 
binucleated cells and displays them in an image gallery with 
the quantified MN count per cell (28,32). The present study 
used the parameters of the classifier of Willems et al (32) 
with minor adjustments. The system allows for the use of 
three different scoring methods, involving varying degrees 
of visual validation of automated scores. The first is the 
‘fully-automated’ scoring method, in which MN counts are 
obtained directly by the MNScore module (32). The second is 
a ‘semi-automated’ scoring method which has been discussed 
in other publications (26,27,38). In the present study, this 
scoring method, which only corrects false positive MN, was 
referred to as semi-automated A. For additional validation, the 
present study introduced a third scoring method, referred to 
as semi‑automated B. In this method, every binucleated (BN) 
cell (with and without MN) was observed in the image gallery 
and false negative MN were corrected, in addition to the false 
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positive MN corrected in semi-automated A. For each sample, 
‘fully-automated’, ‘semi-automated A’ and ‘semi-automated B’ 
MN scores were determined by two experienced scorers. The 
average number of BN cells per data-point was 1,600. Data-
points (per patient/per irradiation dose) with <500 BN were 
not included. All results were normalized to the MN frequency 
in 1,000 BN cells.
The nuclear division index (NDI) was also calculated according 
to the following formula: NDI = (N1 + 2N2 + 3N3 + 4N4)/Ntotal, 
with N1-N4 being the number of cells with 1-4 nuclei and Ntotal 
the total number of cells scored (Ntotal = 500).
Statistical analysis. Statistical analysis was performed using 
Graphpad Prism 6 (GraphPad Inc., La Jolla, CA, USA). 
Differences between means of MN counts in the various groups 
were tested for significance with the Mann‑Whitney U‑test. 
This statistical test was used as it is a non-parametric, distribu-
tion-free test that is suitable for the comparison of groups with 
small sizes where no underlying distribution can be assumed. 
Values are expressed as the mean MN of a patient group/irra-
diation dose. P<0.05 was considered to indicate a statistically 
significant difference between values.
Results
Establishment of an MN scoring method for assessing 
chromosomal radiosensitivity of cervical cancer patients vs. 
that of healthy controls. MN frequencies of cervical cancer 
patients were compared to those of healthy controls using 
the three different scoring methods of the Metafer 4 system. 
Radiation-induced MN yields were calculated by subtracting 
spontaneous MN yields from MN yields in irradiated cells. 
Spontaneous MN values and radiation-induced values for 
2 Gy and 4 Gy are listed in Table I. Using the automated and 
‘semi‑automated A’ scoring method, no significant differences 
were detected between patients and controls. According of the 
results obtained with the ‘semi-automated B’ scoring method, 
patients with cervical cancer had clearly higher MN values 
compared to those of controls for all radiation doses tested; 
the difference between the groups was significant at 2 Gy 
(P=0.0075) and 4 Gy (P=0.0059).
HIV‑positive cervical cancer patients have increased 
chromosomal radiosensitivity compared with that of 
HIV‑negative cervical cancer patients and healthy controls. 
To investigate whether the HIV status affects the chromo-
somal radiosensitivity of cervical cancer patients, the group 
of cervical cancer patients was divided into HIV‑positive 
and HIV‑negative patients. Based on the results shown in 
Table I, the ‘semi-automated B’ scoring method was used 
to compare HIV‑positive and HIV‑negative patients to 
controls. The MN values of healthy controls, HIV‑positive 
patients and HIV‑negative patients are presented in Fig. 1. 
The HIV‑negative patients had clearly higher MN scores and 
therefore a higher chromosomal radiosensitivity compared 
to those of the controls; however, the difference was only 
significant at 4 Gy (P=0.037). For 2 Gy, there was no signifi-
cant difference between HIV‑negative cancer patients and 
controls (P=0.060), while there was a clear shift towards 
higher MN values in the patient group (Fig. 1).
In the HIV‑positive patient group, two samples with 
insufficient BN measured at 4 Gy were excluded from the 
analysis. Although differences were not statistically signifi-
cant, the HIV‑positive patients had higher MN values than the 
HIV‑negative patients. The HIV‑positive patients had signifi-
cantly higher radiation-induced MN values than the healthy 
controls at 2 Gy (P=0.006) and 4 Gy (P=0.008).
HIV‑positive cervical cancer patients have lower NDIs 
than HIV‑negative cervical cancer patients and healthy 
controls. To evaluate the quality of the MN assay in the 
groups of the present study, the nuclear division index 
was calculated. The healthy controls had NDIs of 2.170, 
2.073 and 1.668 at 0, 2 and 4 Gy, respectively, while the 
cancer patients had NDIs of 2.117, 1.883 and 1.535 at these 
radiation doses, respectively. The differences in NDI were 
statistically significant between the two groups at 2 and 4 Gy 
(P=0.0091 and P=0.0182, respectively). The HIV‑positive 
cancer patients had the lowest NDIs among all groups. The 
NDIs for HIV‑positive versus HIV‑negative patients were 
2,074; 1,842; 1,529 vs 2,160; 1,928; 1,535. The NDI of the 
HIV‑positive group was lower than the other groups, but not 
significantly.
Table I. Spontaneous and radiation-induced chromosomal radiosensitivity values for controls (n=20) and cervical cancer patients 
(n=35) determined by micronucleus assay and evaluated using three scoring methods.
 
  Automated   Semi-Automated A   Semi-Automated B
 ------------------------------------------------------------ ----------------------------------------------------------- --------------------------------------------------------------
Group 0 Gy 2 Gy 4 Gy 0 Gy 2 Gy 4 Gy 0 Gy 2 Gy 4 Gy
Controls
  Mean 56 125 323 10 115 317 13 155 454
  SEM 8 8 13 1 5 11 1 6 9
Patients
  Mean 66 144 320 12 124 327 14 179a 506a,b
  SEM 7 9 14 1 4 10 1 5 12
aP<0.05 vs. controls (Mann‑Whitney test); banalysis performed on 33 instead of 35 patients due to insufficient binucleated cell number. SEM, 
standard error of the mean.
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Discussion 
The aim of the present study was to compare the chromosomal 
radiosensitivity of South African cervical cancer patients with 
that of healthy controls using the MN assay. The development 
of the MNScore software module by MetaSystems has allowed 
for the automation of MN scoring (25). The system has been 
documented in several biodosimetric and cancer-associated 
studies and allows for the application of various scoring 
methods that involve varying degrees of visual validation of 
automated scores (26‑32). The presence of apoptotic nuclei 
and a wide range in cell size have been mentioned as factors 
impairing the efficiency of the Metafer system (26,29). Another 
challenge noted is that the system ‘may fail to identify all MN 
if they are close or attached to the main nuclei or if there are 
more than one MN in the same BN cell’ (29). The majority of 
the patient group in the present study had late-stage cervical 
cancer, which may have contributed to apoptosis and variation 
in cell size; furthermore, the doses of irradiation administered 
in vitro may have resulted in multiple MN. For these reasons, 
the present study included a ‘semi-automated B’ scoring 
method as an extra validation step to correct for false positive 
as well as false negative MN in all BN cells detected. While 
‘semi-automated B’ scoring using the Metafer platform is more 
time-consuming than ‘semi-automated A’ scoring, it is more 
rapid than manual scoring under a microscope. Furthermore, 
the Metafer system has additional benefits, including the less 
subjective BN screening and the generation of a full image 
gallery, which can be archived as a ‘virtual slide’ that can 
be re-analyzed whenever necessary. The Metafer platform 
has been used in two similar population studies on breast 
and prostate cancer populations (30,31). Using the auto-
mated scoring only, Varga et al (30,31) were able to clearly 
distinguish between breast cancer patients and controls but 
not between prostate cancer patients and controls. To the 
best of our knowledge, Metafer scoring has not previously 
Figure 1. Radiation‑induced MN yields after 2 Gy and 4 Gy irradiations for cancer patients and controls. Controls (n=20); HIV‑negative patients (n=20); 
HIV‑positive patients (n=15). Midlines indicate the mean MN yield of the group. *P<0.05 vs. controls. HIV, human immunodeficiency virus; MN, micro-
nucleus; pos, posivite; neg, negative; BN, binucleated.
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been used to investigate a cervical cancer population. In the 
present study, when cervical cancer patients were compared to 
controls using the ‘fully-automated’ and ‘semi-automated A’ 
method, no differences were observed between patients and 
controls. However, the ‘semi‑automated B’ scoring method 
determined significantly higher MN values for the patient 
group as compared to those of the control group at 2 and 
4 Gy. At the 4 Gy dose, a significant percentage of BN had 
multiple MN, which was missed by the ‘fully-automated’ and 
‘semi-automated A’ scoring methods. Another reason for the 
inaccuracy of the ‘fully-automated’ and ‘semi-automated A’ 
methods may have been the high level of cell debris that was 
noted on the slides of the cancer patients, which was a possible 
result of increased apoptosis due to elevated radiosensitivity or 
other types of cellular stress associated with late-stage disease. 
The lower yield of binucleated cells in the cancer group, which 
may have also been a result of apoptosis or cellular stress, was 
reflected by the significantly lower NDI compared to that in 
the healthy control group. All of these circumstances may 
have resulted in false positive MN that may have affected the 
automated scoring.
The results of the present study indicated an increased 
chromosomal radiosensitivity in patients with cervical cancer 
compared to that of controls. Previous studies on the chro-
mosomal radiosensitivity of lymphocytes of cervical cancer 
patients have been inconclusive. In a study by Ban et al (22) 
using the MN assay, patients were found to have lower MN 
frequencies than controls. However, the blood samples of 
a large proportion of the patients were taken after or during 
radiotherapy treatment. This resulted in high spontaneous 
MN values, which affected the radiation-induced MN 
values. It was also suggested by the authors that the lower 
MN values determined in cervical cancer patients may be 
the result of an adaptive response of the patients to clinical 
therapy. Encheva et al (39), who performed a similar study 
to the present one, compared MN values of lymphocytes 
from 40 gynecological cancer patients (23 with cervical and 
17 with endometrial cancer combined into one group) to those 
of 10 healthy control subjects. The lymphocytes from the 
combined gynecological cancer patients and the controls had 
similar MN values after exposure to a dose of 1.5 Gy in vitro. 
The inclusion of 17 patients with endometrial cancer makes it 
difficult to draw conclusions on the chromosomal radiosensi-
tivity of cervical cancer patients alone. The present study was 
performed on a cohort of patients with cervical cancer, mainly 
at the late stage.
It is widely accepted that inherited genes have a role in 
cervical cancer susceptibility, as only a fraction of women 
with HPV infection develop cervical cancer, and the disease 
shows familial clustering (40). HPV‑induced cervical carci-
nogenesis is a complex, multi-faceted process that has yet to 
be fully elucidated (7). While numerous studies on cervical 
cancer have focused on genes involved in the immune 
response (41‑43), cervical cancer‑associated genes involved 
in DNA damage repair are also an area of interest. Recent 
studies have shown associations with genes involved in DNA 
damage repair and a risk for cervical cancer (9‑12,44). In addi-
tion, studies have shown that Fanconi Anemia (FA) patients, 
who have deficient DNA damage repair mechanisms, are 
more susceptible to HPV‑positive head and neck squamous 
cell carcinomas compared to non-FA patients with the same 
lesions (45). Park et al (46) reported an association between 
HPV and the FA pathway. Defects in DNA damage‑response 
genes are known to affect chromosomal radiosensitivity (47). 
The increased chromosomal radiosensitivity observed in the 
present study suggested deficient DNA damage response 
signaling, which may have had a role in the genesis of cervical 
cancer. The exact role of DNA damage repair genes in the 
development and progression of cervical cancer remains 
to be fully elucidated. Evidence from a study using retrovi-
ruses showed that when a virus was integrated into the host's 
genome, a double‑strand break (DSB) was formed, causing a 
DNA damage response similar to that observed when cells 
were exposed to ionizing radiation (48). If these DSB are 
not repaired and the integration process is not properly regu-
lated, it can result in genomic instability, which can lead to 
carcinogenesis (12). It was also reported that the preferential 
targets of HPV integration are common fragile sites (49). DNA 
damage repair genes, including ATR, BRCA1, CHK1, have 
been shown to have a role in fragile site stability and expres-
sion (50‑53). There may be a link between compromised DNA 
damage repair, fragile site stability and susceptibility to HPV 
integration and subsequent carcinogenesis.
A previous study by our group showed that HIV‑positive 
individuals were more radiosensitive than non-infected 
individuals (33). HIV infection is common in Africa and 
the epidemiological link between HIV and cervical cancer 
implies that a large number of women seeking treatment 
(often radiotherapy) of the disease are HIV‑positive. For this 
reason, the present study examined a group of HIV‑positive 
cervical cancer patients as part of the study cohort. In two of 
the HIV‑positive patients, the number of BN after the 4 Gy 
dose was too low for the evaluation of the MN score. This was 
likely due to HIV infection, which affects the CD4 count, in 
combination with the late-stage cervical cancer, causing cells 
to not withstand the cytotoxicity of a dose as high as 4 Gy. 
HIV‑positive cervical cancer patients had higher MN values 
than HIV‑negative cervical cancer patients, despite the differ-
ences not being significant. This suggested that HIV infection 
enhanced the radiosensitivity of cervical cancer patients. The 
MN values of HIV‑positive patients were significantly higher 
than those of the healthy controls at 2 Gy and 4 Gy. These 
results were consistent with those of Baeyens et al (33).
The present study showed that when using the Metafer 
system on cancer populations with advanced disease or HIV, 
the ‘semi-automated B’ scoring method yields the most reliable 
results. This technique may also be useful for the assessment 
of the radiosensitivity of population groups with other types of 
cancer. The results also showed that cervical cancer patients 
had higher MN values than those of the controls, suggesting 
increased chromosomal radiosensitivity. The findings of the 
present study confirmed that cervical cancer patients seeking 
radiotherapy who are HIV‑positive may form a distinct group 
that requires individualized treatments. It may be useful to 
follow up the in vitro data with the clinical response of cervical 
cancer patients with HIV infection undergoing radiotherapy. 
Evidence suggested that these patients suffer from increased 
radiation‑induced side‑effects; however, further investigation 
is required to confirm this (54‑56). From the results of the 
present study, it can be deduced that when performing studies 
HERD et al:  CHROMOSOMAL RADIOSENSITIVITY OF HIV/CERVICAL CANCER PATIENTS IN SOUTH AFRICA 135
in developing countries, factors such as the HIV status should 
be considered. Further studies are required to investigate the 
link between chromosomal radiosensitivity, DNA damage 
repair genes and the underlying mechanisms of susceptibility 
to HPV‑induced carcinogenesis. Such studies may identify a 
marker for increased cervical cancer risk in women with HPV 
infection and may assist in the identification of individuals 
requiring regular pap‑smears, which may reduce medical 
expenses in resource-limited countries such as South Africa.
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